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Abstract
Background: Lymphoma is highly associated with HIV in sub-Saharan Africa (SSA), which contributes to worse
outcomes relative to resource-rich settings, and frequent failure of first-line chemotherapy. However, there are no
second-line treatment descriptions for adults with relapsed or refractory lymphoma (RRL) in SSA.
Methods: We describe HIV+ and HIV- patients with RRL receiving salvage chemotherapy in Malawi. Patients were
prospectively treated at a national teaching hospital in Lilongwe, with the modified EPIC regimen (etoposide,
prednisolone, ifosfamide, cisplatin) between June 2013 and May 2016, after failing prior first-line chemotherapy.
Results: Among 21 patients (18 relapsed, 3 refractory), median age was 40 years (range 16–78), 12 (57%) were
male. Thirteen patients (62%) were HIV+, of whom 12 (92%) were on antiretroviral therapy (ART) at initiation of
salvage chemotherapy, with median CD4 cell count 139 cells/μL (range 12–529) and 11 (85%) with suppressed HIV
RNA. Median number of EPIC cycles was 3 (range 1–6), and the commonest toxicity was grade 3/4 neutropenia in 19
patients (90%). Fifteen patients responded (3 complete, 12 partial, overall response rate 71%), but durations were brief.
Median overall survival was 4.5 months [95% confidence interval (CI) 2.4–5.6]. However, three patients, all HIV+,
experienced sustained remissions. Tolerability, response, and survival did not differ by HIV status.
Conclusions: The appropriateness and cost-effectiveness of this approach in severely resource-limited environments is
uncertain, and multifaceted efforts to improve first-line lymphoma treatment should be emphasized, to reduce
frequency with which patients require salvage chemotherapy.
Trial registration: NCT02835911. Registered 19 January 2016.
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Introduction
Lymphoma incidence has increased in sub-Saharan
Africa (SSA) due to human immunodeficiency virus
(HIV) and population aging [1]. While many patients
can be cured, long-term survival remains suboptimal
due to typically advanced disease, limited chemotherapy
formularies and treatment intensity, poor supportive
care without hematopoietic growth factors, limited ac-
cess to targeted agents, and scarce radiotherapy [2–4].
To illustrate, in Malawi, we have reported 45% 1-year
overall survival (OS) for aggressive non-Hodgkin lymph-
oma (NHL) and 75% for classical Hodgkin lymphoma
(HL) [5, 6]. As a result, relapsed or refractory lymphoma
(RRL) is common, for which there is no standard treat-
ment. To our knowledge, there are no published descrip-
tions of salvage treatment for RRL among adults in SSA.
We therefore report our experience with the first
prospectively treated cohort of patients in Malawi
receiving second-line chemotherapy.
Methods
Patients were treated at Kamuzu Central Hospital (KCH)
in Lilongwe, Malawi’s capital. KCH is a national teaching
hospital which provides cancer care to half the country’s
17 million people. At initial diagnosis of lymphoma, all pa-
tients were invited to participate in the KCH Lymphoma
Study longitudinal cohort, for which procedures have been
described in detail [5–7]. The study was conducted in
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accordance with the Helsinki declaration after approval by
the University of North Carolina institutional review
board and Malawi National Health Sciences Review
Committee. All diagnoses were pathologically confirmed
using biopsies supported by immunohistochemistry (IHC)
and weekly real-time telepathology consultation involv-
ing 2–4 Malawian and United States pathologists [8, 9].
First-line treatment was CHOP (cyclophosphamide,
doxorubicin, vincristine, prednisone) for aggressive NHL
and ABVD (doxorubicin, bleomycin, vinblastine, dacarba-
zine) for HL [5, 6]. In this paper, we restricted analyses to
adults >16 years with RRL treated with the modified EPIC
(etoposide, prednisone, ifosfamide, cisplatin) regimen be-
tween June 2013 and May 2016 after prior first-line
chemotherapy.
We were motivated to develop a salvage chemotherapy
program as a result of the frequent clinical need to
palliate RRL patients with significant tumor bulk and
cancer-related symptoms in Lilongwe, often with good
performance status. We chose the modified EPIC
regimen due to lack of cross-resistance with first-line
chemotherapy, drug availability in our environment, and
prior description of its use in high-income countries in
the ambulatory setting without hematopoietic growth
factors and with manageable toxicities [10]. Moreover, the
regimen bears similarity to the more commonly used ICE
(ifosfamide, carboplatin, etoposide) salvage regimen in
resource-rich countries, without requiring high-dose 24-h
infusion of ifosfamide which is impractical in our setting.
Notably, targeted agents including rituximab and brentux-
imab vedotin are not available in the Malawi public sector
for first- or second-line use, nor is radiotherapy.
We administered modified EPIC in Lilongwe as
follows: etoposide intravenously 100 mg/m2 days 1–4,
ifosfamide intravenously 1000 mg/m2 days 1–4; mesna
intravenously at 60% of the ifosfamide dose days 1–4;
prednisolone orally 60 mg/m2 days 1–5; cisplatin intra-
venously 75 mg/m2 day 15. The regimen was adminis-
tered with 28-day cycles. Complete blood count, renal,
and hepatic function were assessed before chemotherapy
administration on days 1 and 15 of each cycle. If abso-
lute neutrophil count (ANC) was less than 0.75 × 103
cells/μL on scheduled day 1, treatment was delayed for
one week until recovery. If ANC was less than
0.75 × 103 cells/μL or serum creatinine was increased by
more than 25% from baseline on scheduled day 15,
cisplatin was omitted. Patients could receive up to six
cycles if responding without severe adverse events re-
lated to therapy. For anti-infective prophylaxis during
treatment, all patients received ciprofloxacin and HIV-
positive patients additionally received fluconazole. HIV-
infected individuals were maintained on antiretroviral
therapy (ART) and cotrimoxazole as per national HIV
treatment guidelines. Tumor response was evaluated
using physical exam, chest x-ray, and abdominal ultra-
sound. Complete response (CR) was defined as reso-
lution of all assessable tumor sites. Partial response (PR)
was defined as >50% reduction of the assessable baseline
tumor burden.
Results
Between June 2013 and May 2016, 21 patients were
treated with modified EPIC in Lilongwe (Table 1).
Median age was 40 years (range 16–78). Thirteen pa-
tients (62%) were HIV-positive, of whom 12 (92%) were
on ART at initiation of salvage chemotherapy, with me-
dian CD4 cell count of 139 cells/μL (range 12–529) and
11 (85%) with suppressed HIV RNA. Aggressive B-cell
NHLs (including diffuse large B-cell lymphoma, Burkitt
lymphoma, plasmablastic lymphoma, and aggressive
B-cell NHL not otherwise specified) were most fre-
quently represented (18, 86%), with most patients
having relapsed disease after prior locally adjudicated
remission (18, 86%), although median time to relapse
after completion of first-line chemotherapy was short
(3.0 months, range 0.7–19.4). Most patients had local-
ized disease (12, 57%), significant tumor bulk (median
6.5 cm, range 3–22), performance status ≤2 (18, 86%),
and preserved bone marrow and kidney function prior
to EPIC initiation.
Treatment course and toxicities for patients receiving
EPIC are shown in Table 2. The median number of cy-
cles was 3 (range 1–6), with disease progression being
the primary reason for therapy discontinuation. Number
of cycles, cumulative dose, and dose intensity were
overall similar between HIV-positive and HIV-negative
patients. Grade 3/4 neutropenia occurred in 19 patients
(90%), and was responsible for only two patients (10%)
receiving at least 50% of planned day 15 cisplatin doses.
Grade 3/4 anemia and thrombocytopenia occurred in 10
(48%) and three (14%) patients, respectively. Grade 3/4
renal dysfunction occurred in only one patient, and of
eight patients with grade 3/4 other non-hematologic
toxicities, these included pain (4), peripheral neuropathy
(3), and nausea/vomiting (1).
Fifteen patients (71%) achieved an objective response
to EPIC [3 CR, 12 PR] compared with baseline. Of three
patients achieving CR, all had HIV-positive NHL (2 dif-
fuse large B-cell lymphoma, 1 plasmablastic lymphoma)
and remained in remission as of August 31, 2016 after
7.2, 14.5, and 15.0 months respectively, including one
patient who was able to travel to India for consolidative
high-dose therapy with autologous stem cell rescue after
achieving CR with EPIC in Malawi. As of August 31,
2016, vital status was known for all 21 patients with no
loss to follow-up. Median follow-up time from EPIC ini-
tiation was 11.2 months (range 5.1–15.0) among patients
still alive. As shown in Fig. 1, median OS 4.5 months
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Table 2 Treatment course and toxicities among patients with relapsed/refractory lymphoma receiving modified EPIC salvage
chemotherapy in Lilongwe
Total (n = 21) HIV+ (n = 13) HIV- (n = 8)
Cycles per patient 3 (1–6) 3 (1–6) 3.5 (1–6)
Days between cycles 28 (25–45) 28 (25–42) 28 (25–45)
Etoposide dose per cycle, mg/m2 100 (48–104) 99 (51–104) 100 (48–102)
Ifosfamide dose per cycle, mg/m2 1000 (482–1042) 993 (511–1042) 1000 (482–1019)
Received >50% of day 15 cisplatin doses, n (%) 2 (10%) 1 (8%) 1 (13%)
Received <4 cycles, n (%) 12 (57%) 8 (62%) 4 (50%)
Progression 11 7 4
Social 1 1 ―
Any grade 3/4 neutropenia, n (%) 19 (90%) 11 (86%) 8 (100%)
Any grade 3/4 anemia, n (%) 10 (48%) 4 (31%) 6 (75%)
Any grade 3/4 thrombocytopenia, n (%) 3 (14%) 1 (8%) 2 (25%)
Any grade 3/4 renal dysfunction, n (%) 1 (5%) 1 (8%) ―
Any grade 3/4 other non-hematologic toxicity, n (%) 8 (38%) 4 (31%) 4 (50%)
Values indicate median (range) unless otherwise specified
Table 1 Baseline characteristics of patients with relapsed/refractory lymphoma initiating salvage chemotherapy in Lilongwe
Total (n = 21) HIV+ (n = 13) HIV- (n = 8)
Age, years 40 (16–78) 49 (16–63) 22 (18–78)
Male, n (%) 12 (57%) 8 (62%) 4 (50%)
Histologic diagnosis, n (%)
Diffuse large B-cell lymphoma 6 (29%) 3 (23%) 3 (38%)
Burkitt lymphoma 2 (10%) ― 2 (25%)
Plasmablastic lymphoma 2 (10%) 2 (15%) ―
Aggressive B-cell NHL NOS 8 (38%) 8 (62%) ―
Classical Hodgkin lymphoma 3 (14%) ― 3 (38%)
Refractory, n (%) 3 (14%) 1 (8%) 2 (25%)
Relapsed, n (%) 18 (86%) 12 (92%) 6 (75%)
Time to relapse from first-line chemotherapy completion, months 3.0 (0.7–19.4) 3.0 (0.7–19.4) 3.6 (0.8–8.1)
Localized disease, n (%) 12 (57%) 10 (77%) 2 (25%)
Largest lymph node mass, cm 6.5 (3–22) 16 (5–35) 11 (2–18)
Performance status ≤2, n (%) 18 (86%) 12 (92%) 6 (75%)
White blood cells, 103/μL 4.6 (2.7–18.6) 4.4 (3.3–8.9) 4.9 (2.7–18.6)
Absolute neutrophil count, 103/μL 2.9 (0.9–14.3) 2.4 (0.9–6.3) 3.0 (1.3–14.3)
Hemoglobin, g/dL 11.2 (6.0–14.7) 12.2 (9.2–14.7) 10.3 (6.0–14.0)
Platelets, 103/μL 332 (56–767) 312 (204–655) 353 (56–767)
Serum creatinine, mg/dL 0.7 (0.3–2.9) 0.8 (0.4–2.9) 0.6 (0.3–1.0)
eGFR <60 mL/min/1.73m2, n (%) 1 (5%) ― 1 (13%)
CD4 count if HIV+, cells/μL ― 139 (12–529) ―
HIV RNA <400 copies/mL if HIV+, n (%) ― 11 (85%) ―
Values indicate median (range) unless otherwise specified
NHL non-Hodgkin lymphoma, NOS not otherwise specified, eGFR estimated glomerular filtration rate
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[95% confidence interval (CI) 2.4–5.6] for the entire
cohort. OS differences were not observed between HIV-
infected patients (median 4.6 months, 95% CI 3.0–5.6)
and HIV-negative patients (median 4.0 months, 95% CI
1.2–7.6). Of fifteen deaths in the study population, all
but two were attributed to progressive lymphoma. Of
three patients with relapsed/refractory HL specifically,
all were HIV-negative, none achieved CR after EPIC,
and two died of progressive HL as of August 31, 2016.
Discussion
In Lilongwe, we found the modified EPIC regimen to be
feasible and well tolerated as salvage treatment for RRL
in a severely resource-limited setting in SSA, for patients
with and without HIV. Most patients responded, al-
though durability of responses was short with limited
OS. Notably, OS was similar to descriptions of salvage
chemotherapy for RRL in resource-rich settings, when
not followed by consolidative high-dose therapy with
autologous stem cell rescue [10].
Our findings highlight an urgent need for better first-
line treatment for lymphoma in SSA [2–5]. Education
efforts for communities and health care workers can facili-
tate earlier referral and diagnosis. Supportive care should
be standardized and refined, with resource-appropriate
incorporation of hematopoietic growth factors. Protocol-
guided chemotherapy with defined strategies for monitor-
ing and dose adjustment should be adopted. Ensuring
continuous chemotherapy supply and incorporating newer
standard-of-care targeted agents is also important, along
with greater radiotherapy availability for patients with
localized, bulky disease. Finally, strategies for more effect-
ively risk-stratified, response-guided treatment are likely
achievable even in the SSA context.
The appropriateness and cost-effectiveness of salvage
chemotherapy for RRL in SSA are uncertain. Escalating
costs of cancer care pose important ethical consider-
ations and threats to health systems even in resource-
rich settings [11, 12]. These issues may be heightened in
settings where there are competing needs to maximize
Fig. 1 Overall survival for patients with relapsed/refractory lymphoma receiving salvage chemotherapy in Lilongwe. a Overall cohort. b Stratified
by HIV status
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public health benefits using limited resources for cancer
control, but also to help individual patients as much as
possible by applying what is locally available. Low
acceptance of palliative care in SSA context has been re-
ported, [13] and in our experience, patients were exten-
sively counseled at the start of salvage chemotherapy
about its anticipated limited duration of benefit, but
almost uniformly elected to be treated when eligible.
Cultural sensitivities may influence patient and provider
willingness to forego active treatment, particularly when
occasional exceptional responses occur. This is illustrated
by three Lilongwe patients who experienced quite long
CRs, including one patient achieving second CR with
EPIC that allowed subsequent high-dose therapy and au-
tologous stem cell rescue consolidation in India. As cancer
programs mature in SSA, developing an appropriate eco-
nomic and ethical framework to optimally apply available
resources will be critical, with strong participation by local
stakeholders, and ‘rationing’ treatment beyond first-line
may be necessary for those most likely to benefit.
Study strengths include prospective, longitudinal follow-
up of RRL cases confirmed using real-time consensus tele-
pathology, supported by IHC and multiple US and Malawi
pathologists. Patients underwent detailed and systematic
clinical characterization, and those with HIV received
concurrent ART in a mature national program. Patients
were actively followed with complete outcome ascertain-
ment. We also made efforts to standardize chemotherapy,
and our study lacked major exclusions. Limitations in-
clude referral bias intrinsic to the Malawi health system,
given centralization of cancer services in Lilongwe and
Blantyre, the two largest cities. Another limitation is ab-
sent death certification in Malawi, leading us to attribute
causation through centralized review.
Conclusion
In summary, salvage chemotherapy using the modified
EPIC regimen was feasible and well tolerated as salvage
treatment for RRL in Malawi. Overall response rates
were high, response durations were short, and OS was
limited although a few patients experienced extended re-
missions. The appropriateness and cost-effectiveness of
this approach in severe resource-limited environments
in SSA is uncertain, and multifaceted efforts to improve
outcomes among newly diagnosed patients in the first
line are paramount, to reduce the frequency with which
patients require salvage chemotherapy.
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